Biology Reference
In-Depth Information
erythropoietin in the heterozygous state.
Blood
94: 2530-2532
72 de la Chapelle A, Traskelin AL, Juvonen E (1993) Truncated erythropoietin receptor causes dom-
inantly inherited benign human erythrocytosis.
Proc Natl Acad Sci USA
90: 4495-4499
73 Tsui FW, Tsui HW (1994) Molecular basis of the motheaten phenotype.
Immunol Rev
138:
185-206
74 Lankester AC, van Schijndel GM, van Lier RA (1995) Hematopoietic cell phosphatase is recruit-
ed to CD22 following B cell antigen receptor ligation.
J Biol Chem
270: 20305-20308
75 Tapley P, Shevde NK, Schweitzer PA, Gallina M, Christianson SW, Lin IL, Stein RB, Shultz LD,
Rosen J, Lamb P (1997) Increased G-CSF responsiveness of bone marrow cells from hematopoi-
etic cell phosphatase deficient viable motheaten mice.
Exp Hematol
25: 122-131
76 Naffakh N, Henri A, Villeval JL, Rouyer-Fessard P, Moullier P, Blumenfeld N, Danos O,
Vainchenker W, Heard JM, Beuzard Y (1995) Sustained delivery of erythropoietin in mice by
genetically modified skin fibroblasts.
Proc Natl Acad Sci USA
92: 3194-3198
77 Bohl D, Naffakh N, Heard JM (1997) Long-term control of erythropoietin secretion by doxycy-
cline in mice transplanted with engineered primary myoblasts.
Nat Med
3: 299-305
78 Naffakh N, Danos O (1996) Gene transfer for erythropoiesis enhancement.
Mol Med Today
2:
343-348
79 Naffakh N, Pinset C, Montarras D, Li Z, Paulin D, Danos O, Heard JM (1996) Long-term secre-
tion of therapeutic proteins from genetically modified skeletal muscles.
Hum Gene Ther
7: 11-21
80 Meyer F, Finer M (2001) Gene therapy: Progress and challenges.
Cell Mol Biol
47: 1277-1294
81 Dalle B, Payen E, Regulier E, Deglon N, Rouyer-Fessard P, Beuzard Y, Aebischer P (1999)
Improvement of mouse beta-thalassemia upon erythropoietin delivery by encapsulated myoblasts.
Gene Ther
6:157-161
82 Payen E, Bettan M, Henri A, Tomkiewitcz E, Houque A, Kuzniak I, Zuber J, Scherman D, Beuzard
Y (2001) Oxygen tension and a pharmacological switch in the regulation of transgene expression
for gene therapy.
J Gene Med
3: 498-504
83 Bohl D, Heard JM (2000) Delivering erythropoietin through genetically engineered cells.
J Am
Soc Nephrol
11: Suppl-62
84 Serguera C, Bohl D, Rolland E, Prevost P, Heard JM (1999) Control of erythropoietin secretion
by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells.
Hum
Gene Ther
10: 375-383
85 Ye X, Rivera VM, Zoltick P, Cerasoli FJr Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM
(1999) Regulated delivery of therapeutic proteins after
in vivo
somatic cell gene transfer.
Science
283: 88-91
86 Maruyama H, Higuchi N, Nishikawa Y, Hirahara H, Iino N, Kameda S, Kawachi H, Yaoita E,
Gejyo F, Miyazaki J (2002) Kidney-targeted naked DNA transfer by retrograde renal vein injec-
tion in rats.
Hum Gene Ther
13:455-468
87 Morlock M, Kissel T, Li YX, Koll H, Winter G (1998) Erythropoietin loaded microspheres pre-
pared from biodegradable LPLG-PEO-LPLG triblock copolymers: Protein stabilization and
in
vitro
release properties.
J Controlled Rel
56: 105-115
88 Pistel KF, Bittner B, Koll H, Winter G, Kissel T (1999) Biodegradable recombinant human ery-
thropoietin loaded microspheres prepared from linear and star-branched block copolymers:
Influence of encapsulation technique and polymer composition on particle characteristics.
J
Controlled Rel
59: 309-325
